News
OncoBeta GmbH® Announces Certification of its New Production Facility Partner MAP Medical Technologies Oy, Tikkakoski FINLAND
OncoBeta GmbH has today announced the certification of its new production facility partner MAP Medical Technologies Oy, Tikkakoski FINLAND, aiming to deliver OncoBeta GmbH’s high-quality products to more patients in a timely manner as well as further address rising patients’ needs. MAP Medical Technologies is a GMP production facility specializing in radiopharmaceuticals which is equipped with OncoBeta’s cutting edge technology to produce our Rhenium-188 compound carpoules in the fight against Non-Melanoma Skin Cancer.
Garching n. Munich, Germany, (June 08, 2018) – OncoBeta GmbH has today announced the certification of its new production facility partner MAP Medical Technologies Oy, Tikkakoski FINLAND, aiming to deliver OncoBeta GmbH’s high-quality products to more patients in a timely manner as well as further address rising patients’ needs. MAP Medical Technologies is a GMP production facility specializing in radiopharmaceuticals which is equipped with OncoBeta’s cutting edge technology to produce our Rhenium-188 compound carpoules in the fight against Non-Melanoma Skin Cancer.
“The new production facility plays a key role in OncoBeta’s global manufacturing network.” Says Shannon D. Brown III, CEO and Managing Director of OncoBeta GmbH. “With this new production facility, we can efficiently service Europe, the entire African continent as well as Canada and Australia. We continuously invest in our technologies to ensure a stable supply of the highest-quality products to physicians and patients around the world. The expanded production capacity will make it possible to meet the increased demand in global markets.”
